The US Food and Drug Administration should give sponsors flexibility in setting enrollment goals for clinical trial diversity action plans and further clarify how to balance enrollment between US and foreign sites in multinational studies, industry groups said.
Key Takeaways
-
Industry groups asked the FDA to provide an example of the type of diversity action plan required under FDORA.
-
PhRMA and BIO seek assurances that the agency will be flexible with enrollment goals in the absence of reliable disease prevalence data
Sponsors also want the option to submit a single diversity action plan for an entire clinical program rather
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?